Navigation Links
NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
Date:12/7/2007

MAPLE GROVE, Minn., Dec. 7 /PRNewswire/ -- NeuroVasx, Inc. announced today the completion of a private placement of common stock in the amount of $8,500,000 with MJSK of Minneapolis, MN and the Stephens Group of Little Rock, AR. Terms of the financing were not disclosed.

The company also announced completion of long term follow up on 20 patients treated with the cPAX Aneurysm Treatment System in a clinical study which was completed in May. The company intends to announce the results of the study at the 2008 International Stoke Conference in February.

"We are very pleased with the results we achieved in our clinical study. The long term follow-up data further supports the clinical effectiveness of cPAX," said Eric Timko, President and CEO of NeuroVasx, Inc. Mr. Timko added, "The company is eager to share the results of our study with the physician community."

Dan Sullivan, Chairman of the Board stated, "The clinical results are a significant milestone for NeuroVasx. We are very pleased with the company's continued progress."

NeuroVasx, Inc. (http://www.neurovasx.com) is a development stage company dedicated to the development of unique catheter and implant technologies to treat acute stroke, aneurysms and other cerebrovascular disorders. Stroke is the third leading cause of death and is the leading cause of adult disability in the United States. The worldwide market potential for stroke treatment devices is estimated to be over $3 billion.


'/>"/>
SOURCE NeuroVasx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... July 10, 2017  US medical equipment and supply ... according to Medical Equipment & Supplies: United ... Focus Reports. Continued increases in demand for medical services ... the population and supported by gains in disposable personal ... supplies. New product introductions will also drive sales as ...
(Date:7/6/2017)... ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, is ... nutrition support. To celebrate its anniversary, ThriveRx recently launched a ... new look with improved organization to create the best user experience for ... ... "We,ve made several great strides ...
(Date:7/1/2017)... 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... conference call will be broadcast live over the Internet on ... news release detailing the quarterly results will be made available ... call. The live audio webcast can be accessed ... It will be archived for replay following the conference call. ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... The Visiting Nurse Association of ... R. Bard Foundation, Inc. to support the music therapy program offered at ... the nonprofit home care agency. Using evidence-based methods, professionally trained and certified music ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is ... product of her research center at Bio-Logic Aqua Research® Water Life Science®, has ... greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will ...
(Date:7/21/2017)... ... July 21, 2017 , ... The most common ... improved quality of life five years after injury, according to research presented today ... Toronto, Ontario, Canada. The study followed patients for five years following surgery. , ...
(Date:7/20/2017)... ... , ... ChenMed , a leading provider of value-based care for seniors, ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine ... Ambulatory Services for the UVA Health System, brings 30 years of highly relevant experience ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Houston, is pleased to announce their expansion to the Midwest with the establishment ... Alysse Hollis and Ronald Bell, and of counsels, John Peck and Robert Bruns, ...
Breaking Medicine News(10 mins):